MedTrace Logo

High Dose Intravenous Fish Oil Reduces Inflammation

NCT04467138 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2020-07-22

No results posted yet for this study

Summary

Retrospective analysis of 51 patients (27 female, 24 male, mean age 51.5±12.6 years) who received all-in-one PN including amino acids, glucose and lipids supplemented with pure fish oil LE was performed.

Conditions

  • Lipid Metabolism Disorders

Interventions

DRUG

Omegaven

Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.

Sponsors & Collaborators

  • Stanley Dudrick's Memorial Hospital

    lead OTHER

Principal Investigators

  • Stanislaw Klek, PhD · 1972

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04467138 on ClinicalTrials.gov